Status:
COMPLETED
Evaluation of the Role of Epstein-Bar Virus in Patients With Pulmonary Arterial Hypertension
Lead Sponsor:
Cairo University
Conditions:
Pulmonary Arterial Hypertension
Eligibility:
All Genders
18+ years
Brief Summary
Evaluate the role of Epstein-Barr virus infection in PAH (Idiopathic and connective tissue disease). This by obtaining a blood sample from the PAH patients undergoing right heart cathetrization as we...
Detailed Description
About Pulmonary Hypertension Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple clinical conditions combined with a variety of cardiovascular and respiratory diseas...
Eligibility Criteria
Inclusion
- Group 1 PAH (Idiopathic ) Group 1 PAH ( Connective tissue disease including SLE, Systemic sclerosis and mixed connective tissue disease) Above 18 years
Exclusion
- Other Groups of Pulmonary hypertension Patients refusing written consent or participation
Key Trial Info
Start Date :
May 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2024
Estimated Enrollment :
78 Patients enrolled
Trial Details
Trial ID
NCT06550648
Start Date
May 1 2023
End Date
April 1 2024
Last Update
August 13 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cairo University- Faculty Of Medicine
Cairo, Egypt, 11562